Intro

This chapter explores a new anti-COVID antiviral drug from Merck seeking emergency use authorization. Highlighting its effectiveness in reducing severe outcomes in at-risk patients, the discussion compares this promising oral treatment to existing therapies.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app